NCT03446157 2026-03-10
Palbociclib and Cetuximab in Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
55 trialsNCT02499146 2026-02-11
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
Pfizer
Phase 1 Completed
NCT02668666 2026-01-20
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT04671615 2025-12-10
A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.
Pfizer
Completed
NCT04735367 2025-12-09
Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole
Pfizer
Completed
NCT02630693 2025-11-25
Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT06086340 2025-11-18
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
Pfizer
Completed
NCT02297438 2025-10-27
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Pfizer
Phase 3 Completed
NCT01907607 2025-08-24
CYCLIGIST
Institut Bergonié
Phase 2 Completed
NCT01356628 2025-07-28
A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
Thomas Jefferson University
Phase 2 Completed
NCT06307457 2025-06-29
A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.
Pfizer
Completed
NCT03844997 2025-05-31
Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT02040857 2025-04-29
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03691493 2025-02-17
ASPIRE
Emory University
Phase 2 Completed
NCT03774472 2025-02-17
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03644186 2024-12-13
TOUCH
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT02491983 2024-12-09
PARSIFAL
MedSIR
Phase 2 Completed
NCT02530320 2024-11-22
Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
Grupo Español de Investigación en Neurooncología
Phase 2 Completed
NCT01740427 2024-11-14
PALOMA-2
Pfizer
Phase 3 Completed
NCT03238196 2024-11-14
Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT03526250 2024-11-01
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT05012644 2024-10-08
Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone
Pfizer
Completed
NCT02028507 2024-09-25
PEARL
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT02913430 2024-09-23
Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib
University of Pittsburgh
Phase EARLY_PHASE1 Completed
NCT04176354 2024-08-23
Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy
Pfizer
Completed
NCT03981614 2024-08-22
Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT03530696 2024-08-13
T-DM1
University of Arizona
Phase 2 Completed
NCT03560531 2024-08-09
A Study of ZN-c5 in Subjects With Breast Cancer
Zeno Alpha Inc.
Phase 1/2 Completed
NCT05361655 2024-06-07
Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor
Pfizer
Completed
NCT03007979 2024-03-20
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
Washington University School of Medicine
Phase 2 Completed
NCT02536742 2024-02-26
PYTHIA
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT02101034 2023-12-21
PD 0332991 and Cetuximab in Patients With Incurable SCCHN
Washington University School of Medicine
Phase 1/2 Completed
NCT05584644 2023-12-19
A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer
Pfizer
Completed
NCT01864746 2023-12-12
PENELOPE-B
GBG Forschungs GmbH
Phase 3 Completed
NCT03054363 2023-11-13
Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
University of Colorado, Denver
Phase 1/2 Completed
NCT02499120 2023-09-08
Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer
Pfizer
Phase 2 Completed
NCT02154490 2023-06-01
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network
Completed
NCT03921866 2023-03-17
ROIS
Pfizer
Completed
NCT04436744 2023-02-02
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)
Hoffmann-La Roche
Phase 2 Completed
NCT02448771 2022-10-24
A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT02871791 2022-08-29
Palbociclib With Everolimus + Exemestane In BC
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT02679755 2022-07-27
Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer
Pfizer
Phase 4 Completed
NCT02384239 2022-03-16
A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer
University of California, San Francisco
Phase 2 Completed
NCT02600923 2022-01-20
Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate
Pfizer
Phase 3 Completed
NCT02296801 2022-01-13
PALLET
NSABP Foundation Inc
Phase 2 Completed
NCT02692755 2021-09-28
PALINA
Georgetown University
Phase 2/3 Completed
NCT03194373 2021-04-12
Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT01037790 2021-03-11
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT01684215 2020-11-23
A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer
Pfizer
Phase 2 Completed
NCT02059213 2020-09-16
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed